| 000 | 01817 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250513111258.0 | ||
| 264 | 0 | _c19970408 | |
| 008 | 199704s 0 0 eng d | ||
| 022 | _a0021-9150 | ||
| 024 | 7 |
_a10.1016/s0021-9150(96)05941-2 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSchaefer, E J | |
| 245 | 0 | 0 |
_aEffects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels. _h[electronic resource] |
| 260 |
_bAtherosclerosis _cNov 1996 |
||
| 300 |
_a113-22 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aApolipoproteins _xblood |
| 650 | 0 | 4 |
_aCholesterol, HDL _xblood |
| 650 | 0 | 4 |
_aCholesterol, VLDL _xblood |
| 650 | 0 | 4 | _aDelayed-Action Preparations |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aGemfibrozil _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypercholesterolemia _xblood |
| 650 | 0 | 4 |
_aHypolipidemic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aLipoproteins _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aTriglycerides _xblood |
| 700 | 1 | _aLamon-Fava, S | |
| 700 | 1 | _aCole, T | |
| 700 | 1 | _aSprecher, D L | |
| 700 | 1 | _aCilla, D D | |
| 700 | 1 | _aBalagtas, C C | |
| 700 | 1 | _aRowan, J P | |
| 700 | 1 | _aBlack, D M | |
| 773 | 0 |
_tAtherosclerosis _gvol. 127 _gno. 1 _gp. 113-22 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0021-9150(96)05941-2 _zAvailable from publisher's website |
| 999 |
_c8997846 _d8997846 |
||